Oncopeptides Reports Sustained Growth and Future Prospects in European Markets

Oncopeptides has announced substantial growth trends, achieving over 30% growth for three consecutive quarters, culminating in an impressive 135% annual increase as reported in their Q2 findings. CEO Sofia Heigis stated the company is on a clear path towards reaching profitability by the end of 2026, fueled by robust sales performance especially in key European markets.

The company's flagship cancer drug, Pepaxti, has gained significant validation by being included in European treatment guidelines for multiple myeloma. Sales for Pepaxti grew by 45% in Q2 compared to the previous quarter, driven by successful pricing negotiations in Germany, Austria, Spain, and Italy. Notably, Oncopeptides' sales team has established a presence in Spain, securing access in 97% of regions, and 80% in Italy, surpassing initial expectations.

To accelerate expansion and invest in its pipeline, Oncopeptides is currently conducting a fully guaranteed rights issue. The potential market for their products in their top four markets is estimated at approximately 1.5 billion SEK. Additionally, the company is negotiating partnerships for the launch of Pepaxti in Japan and pursuing individual patient sales in challenging markets such as Africa and the Middle East.

Oncopeptides is also advancing the development of new drug candidates OPD5 and OPDC3, aimed at addressing additional cancer indications. Heigis emphasized that the initial success of Pepaxti is expected to foster confidence and support in the development of these promising candidates.